NEW YORK (GenomeWeb) - TorreyPines Therapeutics and Eisai have extended an agreement to identify and validate genes that may be used as targets for Alzheimer's drug compounds, TorreyPines said yesterday.
The research collaboration, which the companies began in 2005, is using whole-genome family-based association screening to identify genes associated with Alzheimer's disease.
TorreyPines, based in La Jolla, Calif., will receive an upfront payment and funding for the research for another year, and Eisai will have exclusive rights for first negotiation and refusal for gene targets that come from the research.
TorreyPines said the companies also are involved in a separate agreement to find novel compounds that may be used to treat Alzheimer's disease.
Financial terms of the agreement were not released.